Literature DB >> 1295638

Thrombotic thrombocytopenic purpura: a multimodality model of treatment including plasma exchange, i.v. immunoglobulin, prednisone, antiplatelet agents, vincristine and splenectomy.

J Dervenoulas1, D Karakassis, M Belia, V Pappa, T Economopoulos, E Papageorgiou, A Stavrou, H Bouronikou, S Stylogiannis, S Raptis.   

Abstract

Thirteen patients with thrombotic thrombocytopenic purpura were treated at our facility between 1985 and 1991. All patients were treated with plasma therapy (both plasma exchange and plasma infusions), prednisone, intravenous immunoglobulin, and antiplatelet agents. Twelve patients achieved remission (92.3%). One patient died from cerebral hemorrhage. Vincristine was administered to 5 patients who did not respond after the first two plasmaphereses. Splenectomy was performed in a patient who relapsed four times within a 2-year period. From the 12 patients achieving remission, 11 have been still in remission for a period of 3 to 69 months.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1295638     DOI: 10.1159/000222651

Source DB:  PubMed          Journal:  Infusionsther Transfusionsmed        ISSN: 1019-8466


  1 in total

1.  Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Authors:  Seniz Öngören; Ayşe Salihoğlu; Tuğçe Apaydın; Sevil Sadri; Ahmet Emre Eşkazan; Muhlis Cem Ar; Tuğrul Elverdi; Zafer Başlar; Yıldız Aydın; Teoman Soysal
Journal:  Balkan Med J       Date:  2018-07-03       Impact factor: 2.021

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.